Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.
Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.
Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
August 2024—Bio-Rad Laboratories has launched its Exact Diagnostics GBS positive and negative run controls. The independent quality controls are intended to be used with group B streptococcus molecular assays for evaluating assay performance and testing operator proficiency.
August 2024—Sysmex America announced on July 9 that longtime health care executive Dan Zortman has been named the company’s new CEO. Andy Hay, who has served as CEO since 2021, will continue to serve as chairman and president of Sysmex America with a focus on the company’s emerging Hinotori surgical robotic system business.
August 2024—Qiagen has launched its QIAseq Multimodal DNA/RNA Lib Kit. The kit enables the preparation of DNA and RNA libraries for next-generation sequencing as well as downstream target enrichment based on hybrid capture from a single sample. It offers a streamlined and rapid workflow to generate whole genome and whole transcriptome sequencing libraries from a single sample by combining chemistry optimized for DNA and RNA simultaneously.
August 2024—Bruker Corp. announced the launch of mass spectrometry systems at the American Society for Mass Spectrometry 72nd annual conference on mass spectrometry and allied topics, June 2–6, in Anaheim, Calif.
August 2024—Verichem Laboratories is now offering a multilevel, multianalyte, and ready-to-use Enzyme ER Calibration Verifier kit designed for the calibration verification of enzyme assays on wet chemistry testing systems. The enzyme components within the materials include amylase, alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, cholinesterase, creatine phosphokinase, gamma-glutamyltransferase, lactate dehydrogenase, and lipase and are intended to be treated as patient specimens. The materials have a shelf life and open-vial stability of 18 months.
August 2024—MedTech Breakthrough announced that Epredia has been selected as the winner of best new technology solution—pathology for its SlideMate Laser printer in the 8th annual MedTech Breakthrough Awards program. The SlideMate Laser is designed for clinical laboratories and provides high-resolution, 600-dpi laser printing on microscope slides, enabling laboratories to include more identifying information directly on the tab of the slides. The technology can embed up to 50 characters in a barcode on each slide and offers on-demand and batch printing options. The laser printer’s software can be directly interfaced to a laboratory information system.
August 2024—Roche has launched the Ventana Kappa and Lambda Dual ISH mRNA Probe Cocktail assay in countries accepting the CE mark. The assay is intended for the qualitative detection of kappa and lambda mRNA in formalin-fixed, paraffin-embedded human bone marrow and lymphoid tissue stained on a BenchMark IHC/ISH instrument using chromogenic in situ hybridization and visualized using light microscopy. The test is intended as an aid in the identification of B-cell lymphomas and plasma cell neoplasms. The results of the assay should be interpreted by a qualified pathologist in conjunction with histological examination, relevant clinical information, and proper controls. The product is intended for in vitro diagnostic use.
August 2024—Diasorin announced it has received 510(k) clearance from the FDA for the company’s Liaison Plex Yeast Blood Culture assay, the second molecular multiplexing panel on the Liaison Plex. The assay, which is driven by Gram stain, detects 16 pathogens commonly associated with fungemia. The Liaison Plex sample-to-answer system uses room-temperature consumables, has a hands-on time of two minutes, and produces results in less than two hours.
August 2024—TechLab, a part of SSI Diagnostica Group, announced that its C. Diff Quik Chek Complete test has received certification under European in vitro diagnostic medical device regulation. The test is a rapid membrane enzyme immunoassay designed for the simultaneous detection of Clostridioides difficile glutamate dehydrogenase antigen and toxins A and B in a single reaction well and provides GDH and toxin results within about 30 minutes.
August 2024—Clarapath, a medical robotics company headquartered in Hawthorne, NY, announced it has entered into a strategic collaboration with Mayo Clinic to advance laboratory automation. Clarapath’s SectionStar is an all-in-one tissue sectioning and transfer system that is designed to increase capacity, reliability, and consistency while minimizing the need for highly skilled labor. The collaboration combines Clarapath’s tissue solution and domain experts with the clinical insights and expertise of the Mayo Clinic to enable laboratories to digitally transform the quality, safety, cost, and throughput of their histology process.
